SCHEMBL15948437

SCHEMBL15948437

CCSc1cc(C)n(C)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.39
CYP1A2 P05177 1/20 0.39
BCHE P06276 1/20 0.36
BAZ2B Q9UIF8 1/20 0.35
ALDH1A1 P00352 6/20 0.35
LMNA P02545 3/20 0.35
GLS O94925 1/20 0.34
GAA P10253 1/20 0.34
HPGD P15428 3/20 0.33
ALOX15 P16050 2/20 0.33
HSD17B10 Q99714 2/20 0.33
NPC1 O15118 2/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
TSHR P16473 1/20 0.33
HTT P42858 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
NFKB1 P19838 1/20 0.33
RAB9A P51151 1/20 0.33
NFKB2 Q00653 1/20 0.33
RELA Q04206 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11341067 0.84 KMT2A (0.39) KDM4ECYP1A2BCHEBAZ2BALDH1A1
SCHEMBL16137321 0.79 BCHE (0.33) BCHEBAZ2BALDH1A1LMNA
SCHEMBL11330788 0.76
SCHEMBL17198908 0.69 BAZ2B (0.34) BCHEBAZ2BALDH1A1LMNASMN1; SMN2
SCHEMBL9520576 0.68 KDM4E (0.55) KDM4ECYP1A2ALDH1A1GAAHPGD
SCHEMBL256103 0.67
SCHEMBL15948532 0.66 BCHE (0.42) KDM4EBCHEBAZ2BALDH1A1LMNA
SCHEMBL2268730 0.64 KDM4E (0.34) KDM4ECYP1A2ALDH1A1LMNAHPGD
SCHEMBL15948623 0.64 BCHE (0.35) KDM4ECYP1A2BCHEBAZ2BALDH1A1
SCHEMBL2268724 0.64 ALDH1A1 (0.33) KDM4ECYP1A2ALDH1A1LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3943087-A1 HETEROARYL COMPOUNDS AND USES THEREOF Celgene CAR LLC (BM) 2022-01-26 EP disclosed
US-20170210729-A1 ERK INHIBITORS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY 2017-07-27 US disclosed
US-9663524-B2 Substituted pyrido[2,3-d]pyrimidines as protein kinase inhibitors CELGENE CAR LLC (BM) 2017-05-30 US disclosed
US-9556426-B2 Protein kinase conjugates and inhibitors CELGENE AVILOMICS RESEARCH, INC. (US) 2017-01-31 US disclosed
US-20160046634-A1 HETEROARYL COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY 2016-02-18 US disclosed
US-20150376208-A1 MK2 INHIBITORS AND USES THEREOF CELGENE AVILOMICS RESEARCH, INC. (US) 2015-12-31 US disclosed
US-9145387-B2 ERK inhibitors and uses thereof CELGENE AVILOMICS RESEARCH, INC. (US) 2015-09-29 US disclosed
US-20140228322-A1 ERK INHIBITORS AND USES THEREOF CELGENE AVILOMICS RESEARCH, INC. (US) 2014-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150376208-A1 MK2 INHIBITORS AND USES THEREOF MKNK2, DUSP2, MKNK1 KDM4E 1468/4885CYP1A2 1428/4885BCHE 4379/4885
US-20170210729-A1 ERK INHIBITORS AND USES THEREOF MAP3K20, MAP3K1, MAPK3 KDM4E 1412/4885CYP1A2 3896/4885BCHE 3952/4885
US-20160046634-A1 HETEROARYL COMPOUNDS AND USES THEREOF PRKACA, PRKDC, AURKC KDM4E 2472/4885CYP1A2 3803/4885BCHE 3052/4885
US-20140228322-A1 ERK INHIBITORS AND USES THEREOF MAP3K20, MAP3K1, MAPK3 KDM4E 1412/4885CYP1A2 3896/4885BCHE 3952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.